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Summary  
We found a novel hypofibrinogenemia designated as Matsumoto VII (M-VII), which is 
caused by a heterozygous nucleotide deletion at position g.7651 in FGG and a subsequent 
frameshift mutation in codon 387 of the γ-chain. This frameshift results in 25 amino acid 
substitutions, late termination of translation with elongation by 15 amino acids, and the 
introduction of a canonical glycosylation site. Western blot analysis of the patient’s plasma 
fibrinogen visualized with anti-γ-chain antibody revealed the presence of two extra bands. To 
identify the extra bands and determine which of the above-mentioned alterations caused the 
assembly and/or secretion defects in the patient, 11 variant vectors that introduced mutations 
into the cDNA of the γ-chain or γ’-chain were transfected into CHO cells. In vitro expression 
of transfectants containing γΔ7651A and γΔ7651A/399T (γΔ7651A with an amino acid 
substitution of 399Asn by Thr and a variant lacking the canonical glycosylation site) 
demonstrated a reduction in secretion to approximately 20% of the level seen in the 
transfectants carrying the normal γ-chain. Furthermore, results from other transfectants 
demonstrated that 8 aberrant residues between 391 and 398 of the M-VII variant, rather than 
the 15 amino acid extension or the additional glycosylation, are responsible for the reduced 
levels of assembly and secretion of M-VII variant fibrinogen. Finally, the results of this study 
and our previous reports demonstrate that the fibrinogen γ-chain C-terminal tail (388-411) is 
not necessary for protein assembly or secretion, but the aberrant amino acid sequence 
observed in the M-VII variant (especially 391-398) disturbs these functions. 
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Introduction 
Fibrinogen is a 340-kDa plasma glycoprotein, which consists of two copies of three 
polypeptide chains, Aα, Bβ, and γ, linked by an extensive network of 29 intra- and inter-chain 
disulfide bonds (1,2). The three chains are synthesized, assembled into a hexameric molecule 
in hepatocytes, secreted into the blood, and circulated at 1.8-3.5 g/l. Mature polypeptides of 
the Aα-, Bβ-, and γ-chains are composed of 610, 461, and 411 residues, respectively (1,2), 
and the genes encoding the individual polypeptides are located on chromosome 4 (4q28.1, 
4q28.2, and 4q28.3 for FGG, FGA, and FGB, respectively), as a cluster (3). Furthermore, 
10-15% of plasma fibrinogen contains a heterodimeric molecule that carries a variant chain 
termed the γ’-chain (4), which arises through alternative splicing and polyadenylation of the 
γ-chain mRNA transcript (5). Hypofibrinogenemia or afibrinogenemia, defined as reduced or 
negligible levels of fibrinogen in plasma, can be hereditary. In the past decade, genetic 
abnormalities in patients with these diseases have been found in all three genes and identified 
as missense, nonsense, or frameshift mutations; splice-site abnormalities; or large deletions 
(listed at http://www.geth.org/databaseang/fibrinogen).  
We previously reported on hypofibrinogenemia, which is caused by a missense mutation 
of γ153Cys to Arg (6), and found that the assembly of this variant fibrinogen in CHO cells 
was defective and that the secretion of the variant was impaired. Thereupon, we also 
synthesized a series of fibrinogen variants with truncated γ-chains terminating between 
residues γ379 and the C terminus, γ411 (7). Only variants with γ-chains longer than 386 
residues were secreted into the culture medium, and the synthesis of the variants with 386 
residues or less was markedly reduced in CHO cell lysates. Furthermore, to examine the role 
of fibrinogen γ-chain residue 387Ile in the assembly and secretion of fibrinogen, we 
synthesized a series of variants where γ387 was replaced by Arg, Leu, Met, Ala, or Asp (8). 
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Only variant γ387Asp showed impaired synthesis in the cells and very low secretion into the 
medium. These studies demonstrated that the tertiary structure of the γ-chain C-terminal 
module is important for the assembly of fibrinogen, and more specifically, that the γ387 
residue and/or the conformation of the γ388-411 residues, but not the length of the γC-tail, are 
critical for its assembly and subsequent secretion (7,8).  
Recently, we found a novel variant (Matsumoto VII, M-VII) with a frameshift mutation 
at codon 387 of the γ-chain that results in 25 amino acid substitutions, late termination of 
translation with elongation by 15 amino acids, and the introduction of a canonical 
glycosylation site. Furthermore, Western blot analysis of the patient’s plasma fibrinogen 
visualized with anti-γ-chain antibody revealed two extra bands. In vitro expression of M-VII 
and appropriate C-terminal variants associated with M-VII were used to identify the extra 
bands and to determine which of these alterations causes the assembly and/or secretion 
defects. 
 
Materials and Methods 
Patient 
The patient was a 45-year-old woman who suffered from myoma uteri and had no history of 
bleeding or thrombosis. A routine blood examination showed a low concentration of plasma 
fibrinogen. After the patient provided informed consent, we collected a blood sample for 
biochemical and genetic analyses. This study was approved by the ethics committee of 
Shinshu University, Japan. Although we were not able to analyze other family members, none 
of her family members had a history of bleeding or thrombotic tendency.   
 
Coagulation screening tests 
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Nine volumes of blood were collected in plastic tubes containing 1 vol of 3.2% trisodium 
citrate. The subject’s plasma was separated by centrifugation at 1,500g for 10 min at 4°C. The 
buffy coat was collected and extracted to prepare genomic DNA. Prothrombin time (PT), 
activated partial thromboplastin time (APTT), and the fibrinogen concentration, which was 
determined by the thrombin time method, were measured with an MDA II automated analyzer 
(Biomerieux, Lyon, France). The immunologic fibrinogen concentration was determined by a 
latex photometric immunoassay using antifibrinogen antibody-coated latex particles 
(Mitsubishi Chemical Medience Co., Tokyo, Japan). 
 
Polymerase chain reaction (PCR) amplification and DNA sequence analysis 
To amplify the 5 exons (exon I through V) of the Aα-chain gene, 8 exons (exon I through 
VIII) of the Bβ-chain, and 10 exons (exon I through X) of the γ-chain gene, we designed pairs 
of primers corresponding to the appropriate introns as described previously (6). Genomic 
DNA was isolated from peripheral blood leukocytes as described previously (9). PCR 
amplification and direct sequencing of the DNA fragments extracted from the agarose gels 
were performed as described previously (6,9). 
 
Construction of mutant expression vectors 
The fibrinogen γ-chain expression vector, pMLP-γ, and the fibrinogen γ’-chain expression 
vector, pMLP-γ’, were kindly provided by Lord ST (University of North Carolina) and altered 
by oligonucleotide-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis 
kit (Stratagene, La Jolla, CA) (10) and ten pairs of mutagenesis primers (Table 1). 
 
Recombinant protein expression 
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CHO cell lines that express normal human fibrinogen Aα and Bβ chains, AαBβ-CHO cells, 
were obtained by cotransfecting the plasmids pMLP-Aα, pMLP-Bβ, and pRSVneo into CHO 
cells. The cells were cultured in Dulbecco modified Eagle’s medium Ham nutrient mixture 
F12 supplemented as described previously (DMEM-F12 medium) (11). Each of the variant 
pMLP-γ vectors, original pMLP-γ vector, variant pMLP-γ’-vector, and original 
pMLP-γ’-vector, was cotransfected with the histidinol selection plasmid (pMSVhis) into the 
AαBβ-CHO cell line, using the standard calcium-phosphate coprecipitation method. Colonies 
were selected using G418 (Gibco BRL Rackville, MD) and histidinol (Aldrich Chemical, 
Milwaukee, WI). Individual colonies were expanded in DMEM-F12 medium containing 
G418 and histidinol and examined for fibrinogen synthesis as described previously (12).  
 
Culture medium and cell lysate for immunologic analysis 
The fibrinogen concentrations of the cell lysates and culture media were determined by an 
enzyme-linked immunosorbent assay (ELISA) as described elsewhere (10). Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analysis were 
performed using the enhanced chemiluminescence (ECL) detection reagent (Amersham 
Pharmacia Biotech, Buckinghamshire, United Kingdom) and Hyperfilm-ECL (Amersham 
Pharmacia Biotech) as described previously (7). The cells were grown to confluence in 
60-mm dishes (approximately 1.5-2.0 x 106 cells), and the conditioned medium was harvested 
1 day after confluence (6-8 days after seeding) for immunoblot analysis or ELISA. Cell 
lysates were prepared from the same cultures in 60-mm dishes. The cells were harvested in 
trypsin-ethylene diamine tetraacetic acid (EDTA) solution (Sigma, St Louis, MO), washed 3 
times with phosphate-buffered saline (PBS), and lysed in either 50 µL Laemmli sample buffer 
for immunoblot analysis, or 250 µL 0.1% IGEPAL CA-630 (nonionic detergent; Sigma) and 
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10 mM phenylmethylsulfonyl fluoride (PMSF; Sigma) for ELISA. Rabbit anti-human 
fibrinogen antibody (Ab), anti-human γ-chain monoclonal 2G10 Ab (MAb; specific for 
γ15-35) (13), and anti-human γ'-chain MAb (specific for γ’408-427) (14) were obtained from 
Dako (Carpinteria, CA), Accurate Chemical and Scientific (Westbury, NY), and Upstate 
(Lake Placid, NY), respectively. Horseradish peroxidase conjugated-goat anti-rabbit IgG Ab 
and horseradish peroxidase conjugated-rabbit anti-mouse IgG Ab were purchased from MBL 
(Nagoya, Japan).    
 
Enzymatic elimination of N-linked oligosaccharides in fibrinogen 
Approximately 10-15 µg of fibrinogen, dissolved in 30 µl of 1/15M PBS, 12.5 mM EDTA, 
1.0% IGEPAL, 0.2% SDS, and 1% 2-mercaptoethanol (pH 7.4), was digested with 0.5-1.0 U 
of N-Glycosidase F (Roche, Basel, Switzerland) for 48 hrs at 37 ºC. We then performed 
immunoblot analysis using this sample to investigate the carbohydrate modification of various 
γ- or γ’-chains. 
 
Purification of plasma fibrinogen and factor XIIIa-catalyzed cross-linking of 
Matsumoto VII fibrin  
The purification of fibrinogen from the plasma was performed by a modified 
immunoaffinity-chromatography procedure utilizing IF-1 monoclonal antibody, as previously 
described (9). Eluted fibrinogen was dialyzed against 20 mM N-[2-hydroxyethyl] 
piperazine-N’-[2-ethanesulfonic acid] (HEPES), pH 7.4, containing 0.12 M NaCl. Factor XIII 
(FXIII; 50 units/ml) was activated with human α-thrombin (1 unit/ml) for 60 minutes at 37°C 
in HEPES-buffered saline (HBS) with 5 mM CaCl2. To examine the cross-linking of fibrin, 
fibrinogen (final concentration: 4 mg/ml) was incubated at 37°C with FXIIIa (final 
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concentration: 3.3 units/ml) and human α-thrombin (final concentration: 0.07 units/ml) in 
HBS and 0.67 mM calcium (8). The reactions were stopped after 1 hour by the addition of 
equal volumes of SDS-sample buffer and 2-mercaptoethanol and incubation (5 min) at 100ºC.  
 
Pulse-chase analysis of protein synthesis using [35S]-methionine 
Pulse-chase studies were performed as described previously (6). In brief, for metabolic 
radiolabeling of methionine (Met) residues, γN and γΔ7702A cell lines were grown to 
confluence in 60-mm dishes. The medium was replaced with 1 ml of Met-free DMEM 
supplemented with 1.5 MBq (40 µCi) L-[35S]-Met (MP Biomedicals, Inc., Irvine, CA), and 
the cells were incubated in 5% CO2 for 60 min at 37°C. After being pulsed, the cells were 
rinsed twice, before 1 ml of fresh DMEM containing 20 mM unlabeled L- Met (Wako, Osaka, 
Japan) was added, and the cells were incubated for 0-, 1-, 3-, 6-, and 24-hour chase periods. 
Then, the culture media were harvested, and cell lysates were prepared in 120 µl lysis buffer 
containing 1% IGEPAL CA-630, 150 mM NaCl, 5 mmol/L EDTA, and 10 mM PMSF in 50 
mM Tris-HCl buffer at pH 8.0. Each 500 µl of medium or cell lysate was added to an 
equivalent amount of 1:1000 diluted rabbit anti-fibrinogen polyclonal Ab (Dako) and 
incubated overnight at 4°C, before immunocomplexes were precipitated with Protein 
A-Sepharose (GE Healthcare Ltd., Tokyo, Japan). The precipitates dissolved with Laemmli 
sample buffer were resolved on SDS-polyacrylamide gradient gels. Radioactive bands were 
detected with the Bio-Imaging Analyzer BAS1500 System (Fuji Photo Film Co., Tokyo, 
Japan). 
 
Statistical methods 
Data are presented as means ± SD. Statistical analysis was performed with Welch’s t test 
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using StatFlex (Artec, Osaka, Japan). p values <0.05 were accepted as statistically significant. 
 
Results 
Clinical characterization of the patient 
Routine screening assays before the operation showed impaired coagulation, with normal PT 
and APTT. The subject’s PT was 13.2 sec, whereas the normal range is 11.5 to 15.0 sec. Her 
APTT was 28.7 sec, whereas the normal range is 25.5 to 39.8 sec. Her plasma fibrinogen 
concentration determined by both the thrombin time method (0.77 g/L) and the immunologic 
method (0.89 g/L) was markedly lower than the normal range (1.80 to 3.50 g/L). 
 
Nucleotide-sequence analyses of the fibrinogen gene 
The sequences of the fibrinogen Aα-, Bβ-, and γ-chain genes from the proposita were 
determined by direct analysis of PCR-amplified DNA fragments. An aberrant pattern was 
found in the sequencing fluorogram of the PCR-amplified exon IX of the γ-chain gene from 
the proposita. We subcloned the DNA fragments and found a heterozygous nucleotide 
deletion (A) at position 7651 (all nucleotide positions were numbered by taking the starting 
point of the translation of the γ-chain gene as 1) (GenBank accession number M10014). This 
deletion caused a frameshift mutation in codon 387 and resulted in 25 amino acid 
substitutions (γ387-411), late termination of translation with elongation by 15 amino acids, 
and induction of a potential glycosylation site at codon 399Asn (Table 2). No other mutation 
except those at polymorphic sites was found in either the coding region or in any of the 
exon-intron boundaries. 
 
Immunoblot analysis of fibrinogen in the patient’s plasma 
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To examine how the deletion of γ7651A affects the structure (or construction) of the 
fibrinogen molecule, we performed immunoblot analysis of the patient’s plasma using three 
kinds of Abs as described in Materials and Methods. No difference in the immunoblot pattern 
was observed between the healthy volunteer’s plasma and the patient’s plasma when 
anti-fibrinogen polyclonal Ab was used as the primary Ab. When immunoblotting was 
visualized with anti-γ-chain MAb, a small amount of the γ’-chain was present close to the 
band for the γ-chain in both the healthy volunteer’s and patient’s plasma. However, two extra 
bands, with approximately the same molecular size as the Bβ-chain, one of which had a 
slightly higher molecular weight than the other, were detectable in the patient’s plasma using 
anti-γ-chain MAb. In addition, the latter band was detectable but faint, whereas neither band 
reacted with anti-γ’-chain MAb, which specifically recognizes the C-terminus of the γ’-chain 
molecule (14) (Fig. 1A). Therefore, we speculate that the former extra band is the elongated 
γ-chain (γ*) and the latter is the elongated γ’-chain (γ’*) (Fig. 1A). Densitometric analysis of 
M-VII plasma fibrinogen visualized by anti-γ-chain monoclonal Ab indicated that the 
proportions of the γ-, γ*-, γ’-, and  γ’*-chains were 60 %, 27%, 11%, and 2%, respectively 
(Fig. 1A).  
 
Immunoblot analysis of N-Glycosidase F-treated fibrinogen from the patient’s plasma  
Since the variant fibrinogen of the M-VII proposita had a new potential N-glycosylation site 
at codon 399Asn, we next examined whether these extra bands were derived from 
carbohydrate modification of the fibrinogen molecule on the basis of the deletion of γ7651A. 
For this purpose, we carried out immunoblot analysis using the patient’s plasma, treated with 
N-glycosidase F as described in Materials and Methods. Although the bands of the normal 
Bβ-chain, γ-chain, and γ’-chain were shifted down to a position (Bβ+, γ+, and γ’+, 
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respectively) corresponding to an approximately 4-kDa lower molecule weight by treatment 
with N-glycosidase F, no differences in immunoblot patterns were observed between the 
healthy volunteer’s plasma and the patient’s plasma, irrespective of the treatment with 
N-glycosidase F when using anti-fibrinogen polyclonal Ab or anti-γ’-chain monoclonal Ab 
(Fig. 1B). However, two extra bands of higher molecular weight, which were detected in the 
patient’s plasma using anti-γ-chain monoclonal Ab, disappeared after treatment with 
N-glycosidase F (Fig. 1B). We speculate that the γ*-chain was shifted down to a similar 
position (γ*+) to the normal γ’-chain (γ’+) but that the γ’*-chain disappeared due to the lower 
density of its band (Fig. 1B).  
 
Factor XIIIa-catalyzed cross-linking of Matsumoto VII fibrin  
The variant γ-chain of M-VII was altered at 398Gln and 406Lys residues, both of which are 
essential for the isopeptide bonding between adjacent fibrin molecules by factor XIIIa. To 
confirm the cross-linking ability of the proposita’s fibrin and determine whether the variant 
γ-chain has the ability to clarify the relative amount of the three fibrinogen molecules (normal 
homodimer, variant homodimer, and normal-variant heterodimer) in the proposita’s plasma, 
the factor XIIIa-catalyzed cross-linking of fibrin was performed in the presence of thrombin 
and Ca2+, and the reaction products were analyzed by SDS-PAGE under reducing conditions. 
For normal and proposita fibrin (Fig 1C), the presence of the γ-γ dimer, the γ’-γ’ dimer, and 
the bands corresponding to a higher molecular weight than that of the γ’-γ’ dimer were found 
not to differ from each other upon Coomassie Brilliant Blue R-250 staining and blotting with 
anti-human fibrinogen Ab. In contrast, anti-human γ-chain MAb revealed that variant 
γ-chain, γ*, did not form isopeptide bonds between neighboring normal and variant fibrin 
molecules (Fig 1C). If variant γ-chain had formed γ-γ* and /or γ*-γ* dimers, the relative 
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amount of the three fibrinogen molecules would be revealed by immunoblotting using 
anti-human γ-chain MAb.  
 
Effect of the mutation of the γ-chain on the expression and secretion of fibrinogen 
To define the regulatory region of the γ-chain necessary for the synthesis and secretion of 
fibrinogen, various mutated constructs derived from pMLP-γ (γΝ) were transfected into CHO 
cells followed by the determination of the fibrinogen concentrations in the culture media and 
cell lysates by ELISA. The mutated constructs prepared in this study are summarized in Table 
2. The γΔ7651A/399T (γΔ7651A with amino acid substitution of 399Asn by Thr) construct 
was made to lack a potential canonical glycosylation site at codon 399Asn. As shown in Fig. 
2, both the synthesized fibrinogen in cell lysates (C-Fbg) and the secreted fibrinogen in the 
culture media (M-Fbg) of the transfectants containing γΔ7651A or γΔ7651A/399T were 
significantly reduced compared with those of the transfectants carrying γΝ (p <0.001). 
However, the ratio of the intracellular- to extracellular-fibrinogen content of the transfectants 
carrying γΔ7651A or γΔ7651A/399T was similar to that of the transfectants possessing 
γΝ. Similarly, the C-Fbg and M-Fbg of the transfectants carrying γ’Δ7651 were significantly 
reduced compared with those of the transfectants carrying pMLP-γ’ (γ’N) (p <0.001). In 
contrast, for the other transfectants containing γΔ7689A, γΔ7713G, or γΔ7726T, which 
contained the same sequence as Matsumoto VII beyond γ398, γ407, and γ411, respectively, 
the concentrations of intracellular C-Fbgs (γΔ7713G and γΔ7726T) were significantly reduced 
compared with that of the normal control (p <0.001); however, no statistically significant 
differences in the concentrations of the extracellular M-Fbgs were observed. In addition, the 
levels of secreted extracellular M-Fbgs of the transfectants that contained substitutions close 
to γ387 (γ387S, γ389S, γ390T, γ387S/γ388H, or γ389S/γ390T) were increased rather than 
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reduced. 
 
Immunoblot analysis of the recombinant fibrinogen derived from transfectants 
containing γΔ7651A  
Furthermore, we characterized the recombinant fibrinogen derived from the transfectants 
possessing γΔ7651A by immunoblot analysis under non-reducing or reducing conditions. The 
band of slightly higher molecular weight than plasma fibrinogen and that of recombinant 
normal fibrinogen reacted with anti-fibrinogen polyclonal Ab and was detected in the lysates 
of the transfectants carrying γΔ7651A under non-reducing conditions. When the immunoblot 
analysis was performed under reducing conditions, the extra band of variant fibrinogen was 
hardly detectable using anti-fibrinogen polyclonal Ab. However, as in the immunoblot 
analysis of the patient’s plasma (see Fig. 1A), an extra band of variant fibrinogen with 
approximately the same molecular weight as the Bβ-chain was detected when the anti-γ-chain 
MAb was used. The immunoblot patterns of the culture media were the same as those of the 
lysates for both Abs (Fig. 3A).   
To confirm that the extra band of variant fibrinogen was derived from carbohydrate 
modification of the fibrinogen molecule due to γΔ7651A, we carried out immunoblot analysis 
of the synthesized recombinant fibrinogen in these transfectants, after treating them with 
N-glycosidase F. The bands derived from the recombinant normal Bβ-chain (56.0 kDa) and 
γ-chain (47.5 kDa), and the recombinant variant γ-chain containing γΔ7651A/399T (50.4 kDa) 
(γ**), were shifted down to a position  (Bβ+, γ+, and γ**+, respectively) corresponding to an 
approximately 4-kDa lower molecule weight; however, the recombinant variant γ-chain 
carrying  γΔ7651A (56.0 kDa) (γ*) was shifted down to a position (γ*+) approximately 
corresponding to a 10-kDa difference (Fig. 3B). The 6-kDa difference in the molecular mass 
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caused by N-glycosidase F-treatment between the recombinant variant γ-chains containing 
γΔ7651A/399T (possessing one glycosylation site: γ52Asn) and γΔ7651A (possessing two 
glycosylation sites: γ52Asn and γ399Asn) may have been due to the presence of an additional 
sugar chain and its tertiary structure or negative charges. The calculated molecular weights of 
the N-glycosidase F treated-normal γ-chain and -recombinant variant γ-chains carrying 
 γΔ7651A or γΔ7651A/399T were approximately 43.5 kDa and 46.1 kDa, respectively.   
 
Immunoblot analysis of recombinant fibrinogen derived from transfectants containing 
γ 'Δ7651A  
In the experiments using the lysates and culture media from the transfectants containing 
γ’Δ7651A under non-reducing conditions, PAGE detected a higher molecular weight band 
than that of recombinant normal fibrinogen and γ’-chain containing fibrinogen with 
anti-fibrinogen polyclonal Ab (Fig. 4A) (culture medium data not shown). Under reducing 
conditions, the extra band (γ’*) was detected in a position between the Aα-chain and 
Bβ-chain of normal fibrinogen by immunoblot analysis using anti-fibrinogen polyclonal Ab 
or anti-γ-chain MAb (Fig. 4A). However, in the transfectants containing γ’Δ7651A, the 
variant band did not react with anti-γ’-chain MAb (data not shown).  Similar results were 
obtained for the culture media (Fig. 4A)  
Similar to the results for the normal γ-chain, the molecular weight of the normal γ’-chain 
(53.5 kDa) (γ’) was shifted down to a position (γ’+) corresponding to an approximately 4-kDa 
lower molecule weight by treatment with N-glycosidase F; however, the variant γ’-chain (γ’*) 
(63.2 kDa) derived from the transfectants containing γ’Δ7651A was shifted down to a 
position (γ’*+) corresponding to a slightly lower molecular weight than that of the normal 
Bβ-chain, resulting in an approximately 13-kDa lower molecular weight than the non-treated 
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γ’*-chain (Fig. 4B). The 9-kDa difference in the molecular mass caused by N-glycosidase 
F-treatment between the recombinant variant γ’-chain containing the γ’Δ7651A (possessing 
four glycosylation sites: γ52Asn, γ399Asn, γ406Asn, and γ417Asn) and the normal γ’-chain 
(possessing one glycosylation site: γ52Asn) may have been due to the presence of three 
additional sugar chains and their tertiary structure or negative charges (Table 2). 
 
Pulse-chase analysis of the synthesized fibrinogen 
Finally, using the pulse-chase analysis method as described in Materials and Methods, we 
examined the assembly and secretion of normal and variant fibrinogen containing γΔ7651A.  
As shown in Fig. 5, the cells were incubated with [35S]-Met for 1 hr, the medium was 
replaced with unlabeled-Met, and samples were immunoprecipitated at various times up to 24 
hr.  The specificity and integrity of the immunoprecipitation were verified by the loss of 
labeled bands when excess purified plasma fibrinogen was added to the samples before 
immunoprecipitation (data not shown). Analysis of the lysates from γN cells showed a band 
at 340 kDa, as expected for the intact fibrinogen molecule. This band was clearly present 
prior to the chase, increased in intensity at 1 hour into the chase, and decreased thereafter (Fig. 
5A). Analysis of the culture media showed that radiolabeled fibrinogen was first detected in 
the media following the 1-hour chase. Thereafter, the intensity increased at each time point 
(Fig 5A). The increase in radiolabeled fibrinogen in the medium paralleled the decrease in 
radiolabeled fibrinogen in the cell lysates. Four other immunospecific bands, with relative 
mobilities corresponding to Aα-Bβ-γ complex, and the Aα, Bβ, and γ bands, were detected in 
cell lysates from 1-3-hour chases (Fig 5A). In contrast, analysis of the lysates from γΔ7651A 
cells showed a faint fibrinogen band after 3- and 6-hour chases (Fig 5B), and analysis of the 
culture media showed faint secretion of variant fibrinogen after 24-hour chase (Fig 5B), 
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indicating that the rate of fibrinogen synthesis or assembly was markedly lower in this cell 
line.   
 
Discussion 
We found a novel hypofibrinogenemia caused by a heterozygous nucleotide deletion at FGG 
g.7651 and designated it fibrinogen Matsumoto VII. This nucleotide deletion results in a 
frameshift mutation in codon 387Ile, 25 amino acid substitutions (γ387-411), late termination 
of translation with elongation by 15 amino acids, and the induction of a canonical 
glycosylation site at codon 399Asn (Table 2). Western blot analysis for plasma fibrinogen 
revealed that the elongated γ-chain was present in 27% of γ-chains. Moreover, CHO cells 
expressing FGGΔg.7651 showed reduced secretion of fibrinogen (about 22% of CHO cells 
expressed the wild type). Pulse-chase analysis indicated that the synthesis, assembly, and 
secretion of variant fibrinogen by CHO cells that expressed FGGΔg.7651 were markedly 
impaired. Schmidt et al. also found a novel hypofibrinogenemia caused by a heterozygous 
nucleotide deletion at FGGg.7656 and designated it fibrinogen Heidelberg (Schmidt D et al., 
abstract #59 in XIXth International Fibrinogen Workshop, 2006), in which a frameshift 
mutation in codon 389Phe was found to cause the same substitution and elongation 
(γ389-426) as seen for fibrinogen M-VII (Table 2).  
The variant γ-chain of M-VII was altered at 398Gln and 406Lys residues, both of which 
are essential for γ-γ dimer formation. A factor XIIIa-catalyzed cross-linking experiment 
demonstrated that variant γ-chain did not form the γ-γ dimer between neighboring normal or 
variant γ-chains of fibrin molecules. If the mutant genes are transcribed, translated, 
post-translationally modified, assembled, and secreted at rates similar to normal, we would 
expect that plasma fibrinogen synthesized from heterozygous genes will contain a 1:2:1 
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mixture of normal homodimers, heterodimers, and variant homodimers, respectively. One 
might expect distributions other than 1:2:1 if 1) the variant chain shows impaired assembly 
(6), 2) the assembled protein with altered polypeptide is not stable in the cell (15,16), or 3) the 
assembled protein shows reduced secretion into plasma (15,16,17). For the case of M-VII, our 
results strongly suggest that all three fibrinogen molecules, namely, normal homodimers, 
heterodimers, and variant homodimers, are present in plasma, but the relative amounts of both 
heterodimers and variant homodimers might be less than normal homodimers as shown in Fig 
1A (ratio of normal γ-chain:variant γ-chain was 60:27). Since ELISA and pulse-chase 
experiments demonstrated that variant homodimers were assembled in CHO cells and 
secreted into medium more slowly than normal, we infer that heterodimers are also assembled 
in hepatocytes and secreted into blood. Furthermore, there is a possibility that normal 
fibrinogen synthesis and/or assembly are impeded or reduced by those of variant γ-chain or 
fibrinogen, namely, the so-called dominant-negative phenomenon in the proposita’s 
hepatocytes. It would be interesting to resolve this issue; however, our presented data are 
inadequate to reach a conclusion.  
In order to determine which of these alterations causes the reduced assembly and/or 
secretion of variant fibrinogen, we expressed 10 C-terminal variants associated with M-VII in 
vitro and compared them with the predicted γ’-chain variant. The in vitro expression of these 
variants demonstrated that the aberrant 8 residues between 391 and 398 of the M-VII variant, 
DSQLEKDS, rather than the 15 amino acid extension or the new glycosylation site at Asn399, 
are responsible for the markedly reduced synthesis, assembly, and secretion of M-VII variant 
fibrinogen. This conclusion was confirmed by the expression of the predicted γ’-chain variant 
of M-VII (1-435) in comparison to the wild-type γ’-chain (1-427). Furthermore, we have 
previously reported that the in vitro expression of γIle387Asp indicated markedly reduced 
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assembly and secretion of variant fibrinogen. Since the crystal structure of the γ-module of the 
D region (γ143-392) shows that γ387Ieu lies within a β strand composed of residues γ381-389 
and that this strand is inserted in an antiparallel fashion between strands formed by residues 
γ189-197 and γ243-252 (18,19), the loss or alteration of γ387Ieu results in a change in the 
γ-module and induces defective fibrinogen assembly and secretion. Therefore, the γ387Ile 
residue and/or the conformation of the γC-tail beyond 388, but not the length of the γC-tail, 
are critical for fibrinogen assembly and secretion (8). Since the C-terminal end of the γ-chain 
is flexible, x-ray diffraction analysis has not provided information about the tertiary structure 
of γ391-411 (18,19) except for that of the co-crystal of human γ398-411 linked to the 
C-terminal of chicken egg white lysozyme (20). In contrast, an NMR (nuclear magnetic 
resonance) study of γ385-411 strongly suggested the presence of multiple-turns or helix-like 
structures in residues 390 to 402 (21), and Blumenstein et al. also indicated the presence of 
type II β-turn spanning residues 407 to 410 using the γ392-411 fragment (22). Finally, x-ray 
diffraction analysis and NMR analysis have not provided enough information about the 
normal structure of the 8 residues between 391 and 398, which are substituted in M-VII 
fibrinogen and cause its reduced fibrinogen assembly and secretion.    
Although the strong evolutional and structural association between Bβ- and γ-chain 
molecules is well established (3), the functions of the C-terminal regions in fibrinogen 
assembly and secretion differ. Namely, Vu et al. demonstrated that the C-terminal tail of the 
Bβ-chain (455-461) is necessary for the secretion of fibrinogen but not for its assembly (23), 
whereas the C-terminal tail of the γ-chain (387-411) is necessary for the assembly of 
fibrinogen (7). Two elongation variants in the fibrinogen Bβ-chain caused by a missense 
mutation in the termination codon were reported as dysfibrinogenemia and designated as 
Osaka VI (24) and Magdeburg II (Franke K et al., abstract #T22-48 in XVIIth International 
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Fibrinogen Workshop, 2002), respectively. Both are elongated by 12 amino acids 
(Bβ462-473), and the first amino acids in these variants are Lys and Trp, respectively, whilst 
the other 11 amino acids are the same. These Bβ-chain elongated variants correspond to the 
recombinant γΔ7726T variant, which shows reduced assembly and secretion in comparison to 
the wild type, and they have a complete C-terminal tail with additional aberrant peptides. 
Interestingly, studies of these naturally occurring variants indicated that neither their assembly 
nor secretion processes were impaired, whereas when the extra 472Cys residues form a 
variant fibrinogen homodimer, the aberrant molecules lead to the formation of fragile clots 
made of a lacelike structure composed of highly branched fibers that are thinner than those of 
normal fibrin clots, causing a bleeding tendency in patients (24). On the other hand, naturally 
occurring truncated variants of the Aα-chain indicated that the C-terminal region from 
residues 328 to 610 of the Aα-chain is not necessary for the assembly or secretion of 
fibrinogen (25). 
In conclusion, the results of this study and those of our previous reports demonstrate that 
the 24 amino acids of the fibrinogen γ-chain C-terminal tail (388-411) are not necessary for 
protein assembly or secretion, but aberrant amino acids such as those observed in the M-VII 
variant, especially in the region from 391-398, disturb these functions; however, the aberrant 
extension and/or additional glycosylation observed in the M-VII variant do not severely 
disturb these functions. 
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Tables  
 
Table 1. Primer pairs used for oligonucleotide-directed mutagenesis 
 
Variant plasmid  Oligonucleotide sequence (5’→3’) 
γΔ7651A  CCAATATGAAGATA TCCCATTCAACAGACTCACAATTGG 
γ’Δ7651A 
CCAATTGTGAGTCTGTTGAATGGGA TATCTTCATAGTGG 
CCAATATGAAGATA TCCCATTCAACAGACTCACAATTGG 
CCAATTGTGAGTCTGTTGAATGGGA TATCTTCATAGTGG 
γΔ7651A/399Thr GAGAAGGACAGCACCACCACCTGGGGGG 
 CCCCCCAGGTGGTGGTGCTGTCCTTCC 
γΔ7689A CAATTGGAGAAGGACAGCA CACCACCTGGGGGG 
 CCCCCCAGGTGGTG TGCTGTCCTTCTCCAATTG 
γΔ7713G CTGGGGGGAGCCAAACA GCTGGAGACGTTTAAAAG 
 CTTTTAAACGTCTCCAGC TGTTTGGCTCCCCCCAG 
γΔ7726T CAGGCTGGAGACGTT AAAAGACCGTTTCAAAAG 
 CTTTTGAAACGGTCTTTT AACGTCTCCAGCCTG 
γ387Ser  CCACTATGAAGATAAGCCCATTCAACAGACTCACAATTGG 
 CCAATTGTGAGTCTGTTGAATGGGCTTATCTTCATAGTGG 
γ389Ser CAAGATAATCCCATCCAACAGACTCACAATTGGAGAAGGACAGC 
 GCTGTCCTTCTCCAATTGTGAGCTTGTTGGATGGGATTATCTTC 
γ390Thr CAAGATAATCCCATTCACCAGACTCACAATTGGAGAAGGACAGC 
 GCTGTCCTTCTCCAATTGTGAGTCTGGTGAATGGGATTATCTTC 
γ387Ser/γ388His CCACTATGAAGATAAGCCACTTCAACAGACTCACAATTGGAG 
 CTCCAATTGTGAGTCTGTTGAAGTGGCTTATCTTCATAGTGG 
γ389Ser/γ390Thr GAAGATAATCCCATCCACCAGACTCACAATTGGAGAAGGACAGC 
 GCTGTCCTTCTCCAATTGTGAGTCTGGTGGATGGGATTATCTTC 
 
The 5’-primer is presented above and the 3’-primer below for each mutagenesis. The gaps and 
underlined positions indicate deleted nucleotides, and the bold and underlined letters indicate 
substituted nucleotides. Mutagenesis was performed using 9 pairs of primers and the 
pMLP-γ vector, whereas mutagenesis for  γ’Δ7651A was performed using the primer pairs 
and the pMLP-γ’ vector, and that for γΔ7651A/399T was performed using the primer pairs 
and the pMLP-γΔ7651A vector. In addition, the same primer pairs were used for mutation of 
γΔ7651A and γ’Δ7651A 
 
 
 25 
Table2.  Amino acid sequences of patient and recombinant Fbg γ-chain 
fibrinogen amino acid sequences of Fbg γ-chain C-terminal tail 
number of residues 
γN(=wild type)    
381          391      399 401            411            421 
䊳㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 䊳㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 䊳㻃 䊳㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 䊳㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 㻃 䊳 
KTTMKIIPFN RLTIGEGQQH HLGGAKQAGD V (411) 
Heidelberg        KTTMKIIPST DSQLEKDSNT TWGEPNRLET FKRPFQKRFT FLKDFI (426) 
γΔ7651A(=M-VII) KTTMKISHST DSQLEKDSNT TWGEPNRLET FKRPFQKRFT FLKDFI (426) 
γΔ7651A/399Thr  KTTMKISHST DSQLEKDSTT TWGEPNRLET FKRPFQKRFT FLKDFI (426) 
γΔ7689A KTTMKIIPFN RLTIGEGQHT TWGEPNRLET FKRPFQKRFT FLKDFI (426) 
γΔ7713G  KTTMKIIPFN RLTIGEGQQH HLGGAKQLET FKRPFQKRFT FLKDFI (426) 
γΔ7726T   KTTMKIIPFN RLTIGEGQQH HLGGAKQAGD VKRPFQKRFT FLKDFI (426) 
γ387Ser   KTTMKISPFN RLTIGEGQQH HLGGAKQAGD V (411) 
γ389Ser   KTTMKIIPSN RLTIGEGQQH HLGGAKQAGD V (411) 
γ390Thr    KTTMKIIPFT RLTIGEGQQH HLGGAKQAGD V (411) 
γ387Ser /γ388His   KTTMKISHFN RLTIGEGQQH HLGGAKQAGD V (411) 
γ389Ser/γ390Thr   KTTMKIIPST RLTIGEGQQH HLGGAKQAGD V (411) 
γ’N(=wild type) KTTMKIIPFN RLTIGEGQQH HLGGAKQVRP EHPAETEYDS LYPEDDL (427) 
γ’Δ7651A KTTMKISHST DSQLEKDSNT TWGEPNRSDQ STLRKQNMTH FTLRMICRKL 
  TANFY (435) 
 
The underlined, framed rectangle, and letters with a gray background indicate substituted or 
additional amino acids, a canonical glycosylation site, and the alternative splicing amino acids 
of the γ’-chain. Bold letters indicate amino acids that are the same as those found in M-VII 
fibrinogen. Heidelberg is a fibrinogen with a similar frameshift mutation. The numbers in 
parentheses indicate the numbers of amino acids in the whole chain. The γΔ7651A/399T 
(γΔ7651A with amino acid substitution of 399Asn by Thr) construct was made to lack a 
potential canonical glycosylation site at codon 399Asn. Top line of fibrinogen indicates the 
number of γ-chain residues. 
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Figures  
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Figure 1. Immunoblot analysis of plasma fibrinogen.  Healthy volunteer’s plasma (NP) 
and the patient’s plasma (M-VII) treated without (-) or with N-glycosidase F (+) were 
subjected to 8% SDS-PAGE under reducing conditions (B). Blots were developed with an 
anti-fibrinogen polyclonal antibody, an anti-γ-chain monoclonal antibody (2G10), or an 
anti-γ’-chain monoclonal antibody as described in Materials and Methods. The bands derived 
from normal fibrinogen are indicated as Aα, Bβ, γ, and γ’, and the extra bands derived from 
the patient’s fibrinogen are indicated as γ* and γ’*. In addition, the N-glycosidase F-treated 
bands are indicated as Bβ+, γ+, γ’+, and γ*+. Factor XIIIa-catalyzed cross-linking was 
performed using purified fibrinogen, Factor XIIIa, and α-thrombin. Samples equivalent to 4 
µg or 40 ng fibrinogen were separated on 8% SDS-PAGE under reducing conditions and the 
former were stained with Coomassie Brilliant Blue R-250 and the latter were developed by 
immunoblotting using rabbit anti-human fibrinogen Ab, anti-human γ-chain MAb, and 
anti-human γ'-chain MAb (C). The bands derived from normal fibrin are indicated as α, β, γ, 
γ’, γ-γ dimer, and γ’-γ’dimer and the extra bands derived from the patient’s fibrinogen are 
indicated as γ*. 
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Figure 2. The concentrations of fibrinogen derived from various transfectants.  The 
concentrations of fibrinogen in the cell lysates and the culture media from various 
transfectants were determined by ELISA as described in Materials and Methods. At least 7 
independent clones were tested, and each experiment was performed in triplicate. The 
numbers in parentheses indicate the clone numbers used. The γΔ7651A/399T (γΔ7651A with 
amino acid substitution of 399Asn by Thr) construct was made to lack a potential canonical 
glycosylation site at codon 399Asn. Data are expressed as mean ± SD. *: p <0.05, **: p <0.01, 
and ***: p <0.001 compared with the normal γ transfectant (γN) or the γ’ transfectant (γ’N) 
according to Welch’s t test. 
 
 29 
 
 30 
 
Figure 3. Immunoblot analysis of the recombinant fibrinogen derived from the 
transfectants containing γΔ7651A and γΔ7651A/399T.  Immunoblot analysis of the 
recombinant fibrinogen in CHO cell lysates or in culture media transfected with the normal 
γ-chain (γN), γΔ7651A, or γΔ7651A/399T plasmid. (A) The prepared samples were subjected 
to 8% SDS-PAGE under non-reducing or reducing conditions. Blots were developed with an 
anti-Fbg polyclonal Ab or an anti-γ-chain MAb (2G10). (B) The samples were treated with 
N-glycosidase F as described in Materials and Methods and then analyzed by immunoblot 
analysis as described above. Lane PF indicates purified plasma fibrinogen. The bands derived 
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from normal fibrinogen are indicated as Aα, Bβ, and γ; the variant γ-chains derived from the 
transfectants are indicated as γ* (γΔ7651A) and γ** (γΔ7651A/399T), and the N-glycosidase 
F-treated bands are indicated as Bβ+, γ*+, and γ**+. 
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Figure 4. Immunoblot analysis of the recombinant fibrinogen derived from the 
transfectants containing γ 'Δ7651A.  Immunoblot analysis of the recombinant fibrinogen in 
CHO cell lysates or in culture media transfected with the normal γ-chain (γN), normal 
γ’-chain (γ’N), or γ’Δ7651A plasmid. (A) The prepared samples were subjected to 8% 
SDS-PAGE under non-reducing or reducing conditions. Blots were developed with an 
anti-Fbg polyclonal Ab or an anti-γ-chain MAb (2G10). (B) The samples were treated with 
N-glycosidase F as described in Materials and Methods and then analyzed by immunoblot 
analysis as described above. The bands derived from normal fibrinogen are indicated as Aα, 
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Bβ, and γ’; the variant γ-chain derived from the transfectants is indicated as γ’*, and 
N-glycosidase F-treated bands are indicated as Bβ+, γ’+, and γ’*+. 
 
 
Figure 5. Pulse-chase analysis of the synthesized fibrinogen.  Pulse-chase analysis was 
performed as described in Materials and Methods. The cells were labeled for 1 hour with 
[35S]-methionine and chased for the indicated periods with an excess of unlabeled methionine.  
Immunoprecipitates from the cell lysates or conditioned media were analyzed on 4% to 12% 
gradient SDS-PAGE under nonreducing conditions, and labeled bands were detected by 
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autoradiography. Lane PC in variant was conditioned medium at the 24-hour chase of 
γN-CHO cells as a positive control. Immunoprecipitate bands derived from γN-CHO cells are 
indicated as Fbg, AαBβγ (intermediate complex), Aα, Bβ, and γ, and those from 
γΔ7651A-CHO cells are indicated as Fbg* (variant fibrinogen) and γ* (variant γ-chain). 
  
